WHAT IS CLAIMED IS:

1. Use of an approved drug product comprising apalutamide for the manufacture of a medicament for treating non-metastatic castration-resistant prostate cancer, wherein the approved drug product comprising apalutamide is in a form suitable for administration to a male human with a non-metastatic castration-resistant prostate cancer in combination with androgen deprivation therapy, wherein the approved drug product is present in an amount that is described in a drug product label for said approved drug product, and wherein the median metastasis free survival for a population of male humans who are administered the approved drug product in combination with androgen deprivation therapy is 40.5 months.

2. The use of claim 1, wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.

3. The use of claim 2, wherein the male human has said non-metastatic castration-resistant prostate cancer and has a prostate-specific antigen doubling time (PSADT) that is less than or equal to 10 months.

4. The use of any one of the preceding claims, wherein the male human having said non-metastatic castration-resistant prostate cancer has received at least one prior therapy for the treatment of cancer.

5. The use of claim 4, wherein the prior therapy for the treatment of cancer is bicalutamine or flutamide.

6. The use of any one of claims 1 to 3, wherein the male human having said non-metastatic castration-resistant prostate cancer is treatment naïve.

7. The use of any one of the preceding claims, wherein the male human having said non-metastatic castration-resistant prostate cancer is an adult.

8. The use of any one of the preceding claims, wherein administration of the medicament will result in no more than a grade 3 adverse event.

9. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered daily to the male human.

10. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally on a continuous daily dosage schedule.

11. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally at a dose of about 240 mg per day.

12. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally at a dose of about 60 mg four times per day.

13. The use of any one of the preceding claims, wherein the medicament comprising apalutamide is to be administered orally at a dose of about 240 mg per day, wherein the apalutamide is present in four tablets comprising about 60 mg of apalutamide per tablet.

14. The approved drug product of any one of the preceding claims, wherein the apalutamide is present in four tablets comprising about 60 mg of apalutamide per tablet.

15. The use of any one of the preceding claims, wherein the medicament is present in a solid dosage form.

16. The use of claim 15, wherein the medicament is formulated as a tablet.

17. The use of any one of the preceding claims, wherein the amount of apalutamide that is to be administered is reduced when it is to be co-administered with one or more of:

(a) a CYP2C8 inhibitor, preferably gemfibrozil or clopidogrel; or

(b) a CYP3A4 inhibitor, preferably ketoconazole or ritonavir.

18. The use of any one of the preceding claims, wherein the medicament containing apalutamide is not for use in combination with:

(a) medications that are primarily metabolized by CYP3A4, preferably darunavir, felodipine, midazolam or simvastatin;

(b) medications that are primarily metabolized by CYP2C19, preferably diazepam or omeprazole;

(c) medications that are primarily metabolized by CYP2C9, preferably warfarin or phenytoin; or

(d) medications that are substrates of UGT, preferably levothyroxine or valproic acid.

19. The use of any one of the preceding claims, wherein the medicament containing apalutamide is not for use in combination with:

(a) medications that are P-gp substrates, preferably fexofenadine, colchicine, dabigatran etexilate or digoxin; or

(b) BCRP/OATP1B1 substrates, preferably lapatinib, methotrexate, rosuvastatin, or repaglinide.